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would seem most relevant to different stakeholders. Methods: A landscape review 
was performed in Medline and EMBASE. Initial search retrieved over 2000 articles. 
After a selection based on reference to healthcare, policy issues, or social justice, 
64 papers were included. Data were extracted and a full table was made, including 
all arguments found; next, identical or largely overlapping criteria were excluded 
and a reduced set was compiled. Results: The final set included 26 arguments, 
categorized by type (clinical, social justice, ethical, and policy). Examples of argu-
ments included in the final set are: Longevity, need, dignity and public health value. 
For each argument, relevance to stakeholders was scored on three levels (not, partly, 
and completely relevant). ConClusions: Many arguments play a role in making 
decisions about patient treatments, but not all are relevant to all interventions. 
Moreover, they may interact with each other. Therefore, systematic and analytical 
approaches such as multi-criteria decision analysis may be not suitable. As such, a 
viable way to deal with interacting and possibly conflicting arguments might be to 
arrange public discussions that would evoke different stakeholders’ perspectives.
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objeCtives: FDA breakthrough therapy designation was created in 2012 to expedite 
the registration of new health care technologies for use by patients with serious or 
life-threatening diseases/conditions. Breakthrough therapies are eligible for other 
FDA regulatory programs such as fast track designation, accelerated approval and 
priority review. We sought to determine whether other regulators and HTA agen-
cies/payers also sought to expedite access to these therapies. Methods: The FDA 
website was examined to identify breakthrough therapy medicines that had been 
approved up to 31 December 2014. The websites of the EMA (EU), Health Canada and 
TGA (Australia) were examined to determine their corresponding registration status. 
The NICE (England), IQWiG (Germany), TC (France), CADTH/pCODR (Canada) and 
PBAC (Australia) websites were examined to determine if and when the medicines 
had been considered for reimbursement/coverage. Results: The FDA approved 
14 breakthrough medicines as at 31 December 2014 for use in 16 unique patient 
populations (i.e. pairings). The mean time from submission to approval was 164 
days. Twelve pairings are orphan drugs and 9 are for patients with cancer. As of 
20 June 2015, 13 had been registered in the EU (mean time 326 days), 8 in Canada 
(275 days) and 9 in Australia (N/A). Four of the 15 pairings had been assessed by 
NICE (all recommended), 5 by IQWiG (4 additional benefit not quantifiable, 1 minor 
additional benefit), 6 by the TC (ASMR rating = II (2), III (1), IV (1), V (2)), 8 by CADTH/
pCODR (6 recommended, 2 not recommended) and 7 by the PBAC (all recom-
mended). ConClusions: Most of the 16 pairings were registered first in the US. 
The FDA evaluation period was shorter compared to other regulatory agencies. Some 
HTA agencies are yet to consider many pairings whilst others have dissimilar views 
on their additional clinical benefit.
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objeCtives: This research aims to characterize the extent to which health tech-
nology assessment (HTA) is currently being used to determine pharmaceutical 
coverage in the Middle East and North Africa (MENA) region. The objectives are 
to understand which decision-makers are currently undertaking this activity, the 
extent of its formalization, and in which parts of the healthcare system in each 
country there is greatest appetite for its implementation. Methods: In-depth, 
qualitative interviews were conducted with a total of 11 payer decision-makers 
and 20 industry stakeholders in Egypt, Saudi Arabia, Turkey and the United Arab 
Emirates (UAE). Published literature and government websites were also reviewed. 
Primary and secondary research focused on current and evolving reimbursement 
decision-making procedures in these countries in addition to potential policy 
reforms. Results: Of the countries considered, HTA focused on evaluation of 
specific pharmaceuticals appears to have gained the most traction in Saudi Arabia, 
where one of the public-sector payers has begun undertaking in-depth pharma-
coeconomic (PE) analysis. In Egypt, while a PE unit has been established, its pre-
sent role is to support the country’s Drug Pricing Committee on a case-by-case 
basis. In Turkey, while PE data is required for reimbursement submission, budget 
impact is reported to remain the primary driver of national-level decision-mak-
ing. Meanwhile, in the UAE, there is little evidence that the insurers increasingly 
responsible for coverage under the country’s healthcare reforms are using formal 
HTA. ConClusions: The extent of HTA formalization and the specific areas of 
the healthcare system in which HTA operates vary across the MENA region, in 
line with the broader policy framework. Champions of further HTA development 
come from diverse stakeholder groups in each country. With time, it is expected 
that HTA will gain increasing traction across MENA, alongside arrangements 
such as risk-sharing schemes, with significant consequences for pharmaceutical 
access.
PHP211
orPHan drugs assessMent in gerMany: a coMParison witH otHer 
international Hta agencies
Mycka J1, Dellamano R2, Lobb W1, Dellamano L2, Dalal N1
1Medical Marketing Economics LLC (MME), Montclair, NJ, USA, 2ValueVector, Milan, Italy
objeCtives: Examine orphan drugs assessed by the German Federal Joint 
Committee (G-BA) between January 2011 and May 2015 and compare their 
assessments with those of other international HTA agencies. Methods: GBA 
guidlines and pricing and reimbursement legislation. Results: The survey analyses 
pharmacoeconomic guideline of the National Council on prices and reimburse-
ment for inclusion of new INN in the positive drug list in Bulgaria. Requirements 
for efficacy, safety, benefits, adverse events, comparator, standard treatment, drug 
utilization, budget impact, patient population during the premarketing and post-
marketing period are change in order to provide data with higher quality for the 
decision making process . From April 2013 to July 2015. Over that period more than 
36 new INNs were accepted for reimbursement in Bulgaria. A guideline with an HTA 
approach for assessment of submitted dossiers was introduced in April 2015 The 
experience in that field of other MSs is summarized and compared. ConClusions: 
The study evaluates how NCPR develops recommendations and reimbursement 
decisions on the basis of one step procedure which shortens the pricing and reim-
bursement process in comparison with other EU MSs. No published criteria how to 
evaluate the submitted pharmacoeconomic information by the expert of the NCPR 
are publicly available and HTA appraisal may be subjectively biased.
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objeCtives: For orphan drugs an additional benefit is granted by market authori-
zation of the EMA. In case orphan drugs exceed an annually turnover of 1m Euro 
(based on ex. pharmacy prices) in the outpatient sector recently authorized orphan 
drugs have to undergo an assessment of the additional benefit extent by the Federal 
Joint Committee. Based on the results pharmaceutical manufacturer and the head 
association of the statutory health insurance negotiate rebates. The objective of this 
analysis is to assess whether the additional benefit extent of orphan drugs does 
impact the rebate size of the price negotiations. Methods: In a first step orphan 
drugs affected by an assessment of additional benefit extent were analyzed within 
the German market. The dependency between additional benefit extent and rebate 
size of negotiations is assessed by correlation analysis. This analysis is based on 
relevant public available data of the Federal Joint Committee as well as price related 
rebate information related to the AMNOG process for orphan drugs. Results: By 
May 2015, 10 of currently 77 in Germany registered orphan drugs passed the AMNOG 
legislation comprising the assessment of additional benefit extent as well as associ-
ated price negotiations. Thereby rebates sizes ranging from 9% up to almost 44%. 
The analysis of the additional benefit extent and the rebate size showed no correla-
tion between the two parameters. ConClusions: The hypothesis of an inversely 
proportional dependence between additional benefit extent and rebate size was 
refuted by this analysis. Following this a larger benefit extent tends not to impact 
price negotiations in terms of a rebate reduction. However, the small sample size 
tends to limit power of the analysis.
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objeCtives: Canadian provinces are encouraged to follow HTA recommendations 
conducted under pCODR for cancer drugs, but have ultimate authority over the 
final reimbursement decision on public drug plans. In order to understand the 
impact of HTA assessments on market access of oncology drugs and highlight vari-
ations across the individual jurisdictions we conducted a quantitative analysis of 
all pCODR’s oncology assessments completed in 2013-14 and consequent fund-
ing decisions implemented by the provinces. Methods: Data, obtained from the 
pCODR database for all 27 assessments completed in 2013 and 2014, were used to 
estimate median time to pCODR final decision and the time to first funding approval 
in one of the nine provinces excluding Quebec. We also examined the probability 
of obtaining public drug plan approval in Canada based on the pCODR recommen-
dation. Results: On average, 74% of the assessments resulted in a favourable 
decision by the provinces, compared to 88% with a favourable pCODR recommen-
dation. However, positive provincial funding decisions varied considerably (88% in 
Ontario, Manitoba, and Saskatchewan, to 32% in Prince Edward Island). At the time 
of analysis 16% of drugs were still awaiting provincial funding assessment, while 
10% received no funding primarily after a “no funding” pCODR recommendation. 
The median time between marketing approval and a final pCODR decision was 200 
days; the median time between that final decision and receiving the first fund-
ing approval was 115 days. Provincial funding decisions under pCPA joint negotia-
tions took longer (median of 118 days) compared to those negotiated separately (80 
days). ConClusions: It takes nearly four months for provinces to begin funding 
new drugs after a final HTA decision is issued, with funding decisions in other 
jurisdictions lagging further behind. Multiple levels of pricing and reimbursement 
regulations and a highly fragmented pharmaceutical market are likely impacting 
market access for new drugs in Canada.
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objeCtives: The healthcare sector is evolving while life expectancy is increasing. 
These trends put greater pressure on resources, prompt reforms, and demand trans-
parent arguments and criteria to assess the overall value of health interventions. 
Besides (cost) effectiveness, many criteria play a role when determining the value 
of interventions. There is no consensus on the core arguments. This study aimed at 
retrieving the most widely recognized arguments used in making decisions about 
patient treatments and prioritizing interventions, and to compile a smaller set that 
